Letter to Editor
BibTex RIS Cite

The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions

Year 2020, Volume: 3 Issue: 3, 81 - 83, 31.12.2020
https://izlik.org/JA55GY36JS

Abstract

COVID-19 is a new Coronavirus disease that researchers have reported older age, male gender, and comorbidity are associated with a higher risk of severe disease and mortality. Unfortunately, there is no sufficient supporting evidence that any potential therapy improves outcomes in patients diagnosed with COVID-19. Currently, one of the most popular potential treatment options is hydroxychloroquine. However, it also has serious adverse effects (<10%), including QTc prolongation with a possible risk of torsades de pointes, hypoglycemia, neuropsychiatric effects, and retinopathy. Therefore, careful monitoring is required during hydroxychloroquine treatment, and there is an urgent need to develop safe and effective drugs to treat COVID-19 potentially.

Project Number

yok

References

  • 1. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American journal of Chinese medicine. 2020 Mar; 13:1-26.
  • 2. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: a single-center experience in Turkey between 2013 and 2017. Clinical interventions in aging. 2018; 13:1899-1905.
  • 3. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 May; 323(18):1824-1836.
  • 4. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun ;8(6):539-541.
  • 5. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun; 382(25):2411-2418.
  • 6. Dixon DL, Van Tassell BW, Vecchie A, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of cardiovascular pharmacology. 2020 May;75(5):359-367.
  • 7. https://www.covid19-druginteractions.org/. Accessed in 6th July 2020.
  • 8. Lexicomp® Drug Interactions. https://www.uptodate.com/drug-interactions/#di-druglist. Accessed in 7th July 2020.
  • 9. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed in 6th July 2020.
  • 10. U.S. Food & Drug Administration News Release: Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed in 18th June 2020.

Yaşlı COVID-19 Hastalarında Tedavinin Güçlükleri ve Potansiyel İlaç Etkileşimleri

Year 2020, Volume: 3 Issue: 3, 81 - 83, 31.12.2020
https://izlik.org/JA55GY36JS

Abstract

COVID-19, araştırmaların ileri yaş, erkek cinsiyet ve komorbiditenin daha şiddetli hastalık ve ölüm riski ile ilişkili olduğunu bildirdiği yeni bir koronavirüs hastalığıdır. Ne yazık ki, herhangi bir potansiyel tedavinin COVID-19 teşhisi konan hastalarda sonuçları iyileştirdiğine dair yeterli destekleyici kanıt yoktur. Şu anda en popüler potansiyel tedavi seçeneklerinden biri hidroksiklorokindir. Ancak hidroksiklorokin, QTc uzaması ile birlikte olası torsades de pointes riski, hipoglisemi, nöropsikiyatrik etkiler, retinopati gibi ciddi yan etkilere (<% 10) neden olabilmektedir. Bu nedenle, hidroksiklorokin tedavisi sırasında dikkatli izlem gereklidir ve COVID-19'u tedavi etme potansiyeline sahip güvenli ve etkili ilaçların geliştirilmesine acil ihtiyaç duyulmaktadır.

Supporting Institution

yok

Project Number

yok

Thanks

yok

References

  • 1. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American journal of Chinese medicine. 2020 Mar; 13:1-26.
  • 2. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: a single-center experience in Turkey between 2013 and 2017. Clinical interventions in aging. 2018; 13:1899-1905.
  • 3. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 May; 323(18):1824-1836.
  • 4. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun ;8(6):539-541.
  • 5. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun; 382(25):2411-2418.
  • 6. Dixon DL, Van Tassell BW, Vecchie A, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of cardiovascular pharmacology. 2020 May;75(5):359-367.
  • 7. https://www.covid19-druginteractions.org/. Accessed in 6th July 2020.
  • 8. Lexicomp® Drug Interactions. https://www.uptodate.com/drug-interactions/#di-druglist. Accessed in 7th July 2020.
  • 9. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed in 6th July 2020.
  • 10. U.S. Food & Drug Administration News Release: Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed in 18th June 2020.
There are 10 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Letter to Editor
Authors

Esra Ateş Bulut 0000-0002-1124-9720

Pinar Soysal 0000-0002-6042-1718

Ahmet Turan Işık 0000-0001-5867-6503

Project Number yok
Submission Date October 12, 2020
Acceptance Date December 15, 2020
Publication Date December 31, 2020
IZ https://izlik.org/JA55GY36JS
Published in Issue Year 2020 Volume: 3 Issue: 3

Cite

APA Ateş Bulut, E., Soysal, P., & Işık, A. T. (2020). The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. Geriatrik Bilimler Dergisi, 3(3), 81-83. https://izlik.org/JA55GY36JS
AMA 1.Ateş Bulut E, Soysal P, Işık AT. The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. JoGS. 2020;3(3):81-83. https://izlik.org/JA55GY36JS
Chicago Ateş Bulut, Esra, Pinar Soysal, and Ahmet Turan Işık. 2020. “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”. Geriatrik Bilimler Dergisi 3 (3): 81-83. https://izlik.org/JA55GY36JS.
EndNote Ateş Bulut E, Soysal P, Işık AT (December 1, 2020) The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. Geriatrik Bilimler Dergisi 3 3 81–83.
IEEE [1]E. Ateş Bulut, P. Soysal, and A. T. Işık, “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”, JoGS, vol. 3, no. 3, pp. 81–83, Dec. 2020, [Online]. Available: https://izlik.org/JA55GY36JS
ISNAD Ateş Bulut, Esra - Soysal, Pinar - Işık, Ahmet Turan. “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”. Geriatrik Bilimler Dergisi 3/3 (December 1, 2020): 81-83. https://izlik.org/JA55GY36JS.
JAMA 1.Ateş Bulut E, Soysal P, Işık AT. The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. JoGS. 2020;3:81–83.
MLA Ateş Bulut, Esra, et al. “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”. Geriatrik Bilimler Dergisi, vol. 3, no. 3, Dec. 2020, pp. 81-83, https://izlik.org/JA55GY36JS.
Vancouver 1.Esra Ateş Bulut, Pinar Soysal, Ahmet Turan Işık. The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. JoGS [Internet]. 2020 Dec. 1;3(3):81-3. Available from: https://izlik.org/JA55GY36JS

Creative Commons Lisansı

Articles published in this journal are licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


Journal of Geriatric Science is indexed in EBSCO, Turkey Citation Index, Turkish MEDLINE, Asos Index, Scilit and in ULAKBIM TR-INDEX as of the 2023-2024 issues.




34874     34790                31219                 |                | 24435    |                       24370    

24026                 |    17423    |                  scholar_logo_64dp.png     |          24050